You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

immunophenotype

Showing 1 - 25 of 242
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Sepsis, Septic Shock, Sepsis Syndrome Trial in Nanjing

Enrolling by invitation
  • Sepsis
  • +2 more
    • Nanjing, Jiangsu, China
      Department of Critical Care , Zhong-da Hospital
    Oct 29, 2022

    Immune-related Adverse Events Refractory to Standard Therapy and

    Recruiting
    • Immune-related Adverse Event
    • Extracorporeal photopheresis
    • Other immunosuppressive or immunomodulatory drugs
    • Munich, Germany
      LMU Klinikum Hauttumorzentrum
    Jan 17, 2023

    Circulating and Tumor-infiltrating Immune Cells in Malignant

    Recruiting
    • Brain Tumor, Primary
    • Brain Tumor - Metastatic
    • Circulating leukocytes immunophenotype
    • Tumor sampling
    • Milan, Italy
      IRCCS San Raffaele Scientific Institute
    Apr 14, 2023

    Immunophenotype of Risk in Older Patients Admitted for Pneumonia

    Active, not recruiting
    • Age Associated Immune Deficiency
    • +5 more
    • no intervention
    • Barcelona, Spain
      Hospital de la Santa Creu i Sant Pau
    Nov 22, 2021

    Acute Myeloid Leukemia Trial in Italy (tagraxofusp)

    Recruiting
    • Acute Myeloid Leukemia
    • Bergamo, Italy
    • +7 more
    Dec 17, 2021

    Leukocyte Immunophenotype and Lipid Transport System as

    Unknown status
    • Sepsis
    • +2 more
    • Bood leukocyte subsets
    • The cholesterol content of the cell membrane of T-cells and monocytes
    • Minsk, Belarus
      The Republican Research and Practical Center for Epidemiology an
    Nov 24, 2019

    B-All, Acute Lymphoblastic Leukemia Trial run by the National Cancer Institute (NCI) (NGS testing)

    Not yet recruiting
    • B-All
    • Acute Lymphoblastic Leukemia
    • NGS testing
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Feb 2, 2023

    Gastric Cancer Trial in ZhengZhou (SHR1210 combined with FOLFOX)

    Active, not recruiting
    • Gastric Cancer
    • SHR1210 combined with FOLFOX
    • ZhengZhou, Henan, China
      Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
    Jan 11, 2022

    Tumor Microenvironment

    Active, not recruiting
    • Lung Adenocarcinoma
      • (no location specified)
      Aug 5, 2023

      AML Patients After Stem Cell Transplant to Understand Relapse

      Recruiting
      • Acute Myeloid Leukemia in Remission
      • Prospective determination of the clinical utility of measurable residual disease (MRD) testing
      • Duarte, California
      • +3 more
      Dec 7, 2022

      Malignant Sarcoma Trial in Madrid (Natural Killer (NK) cells (a new immunotherapy))

      Recruiting
      • Malignant Sarcoma
      • Natural Killer (NK) cells (a new immunotherapy)
      • Madrid, Spain
        Hospital Universitario La Paz
      Jul 19, 2023

      Acute Myeloid Leukemia Trial in Columbus (Universal Donor Natural Killer Cells)

      Recruiting
      • Acute Myeloid Leukemia
      • Universal Donor Natural Killer Cells
      • Columbus, Ohio
        Nationwide Children's Hospital
      Aug 11, 2022

      Endometriosis, Endometriosis-related Pain Trial in Milan (Blood, fecal, vaginal and endometrial liquid samples)

      Recruiting
      • Endometriosis
      • Endometriosis-related Pain
      • Blood, fecal, vaginal and endometrial liquid samples
      • Milan, Italy
        Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
      Jun 22, 2022

      CLL/SLL Trial in France (First line therapy)

      Not yet recruiting
      • CLL/SLL
      • First line therapy
      • Amiens, France
      • +57 more
      Oct 21, 2022

      T-Acute Lymphoblastic Leukemia, Adult T Lymphoblastic Lymphoma Trial in United States (BL-8040, Nelarabine)

      Terminated
      • T-Acute Lymphoblastic Leukemia
      • Adult T Lymphoblastic Lymphoma
      • Saint Louis, Missouri
      • +1 more
      Jan 18, 2023

      Primary Sclerosing Cholangitis Trial in Redwood City, Stanford (Hymecromone)

      Not yet recruiting
      • Primary Sclerosing Cholangitis
      • Redwood City, California
      • +1 more
      Nov 1, 2022

      Anaplastic Lymphoma Kinase Gene Translocation, NSCLC Trial in Boston

      Recruiting
      • Anaplastic Lymphoma Kinase Gene Translocation
      • Non-Small Cell Lung Cancer
        • Boston, Massachusetts
          Massachusetts General Hospital Cancer Center
        Jan 14, 2022

        Adjuvant Radiotherapy of Non-metastatic Breast Carcinoma With

        Recruiting
        • Tumor Cell, Circulating
        • Adjuvant radiotherapy
        • neoadjuvant and adjuvant chemotherapy
        • Jena, Germany
          Department of Radiooncology, Jena
        Sep 28, 2021

        Immunological Disease, Autoimmune Diseases, Primary Immune Deficiency Trial in New York

        Recruiting
        • Immunological Disease
        • +2 more
          • New York, New York
            Mount Sinai
          Apr 13, 2022

          HIV Infection Trial in Italy, Netherlands, Spain (Analytical Treatment Interruption + bNAbs infusion)

          Withdrawn
          • HIV Infection
          • Analytical Treatment Interruption + bNAbs infusion
          • Milan, Lombardy, Italy
          • +3 more
          Aug 2, 2022

          Knee Arthroplasty, Total Trial in Vail (Losartan, Placebo - Losartan)

          Not yet recruiting
          • Knee Arthroplasty, Total
          • Vail, Colorado
            The Steadman Clinic
          Oct 26, 2023

          Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Columbus (procedure, drug, biological)

          Not yet recruiting
          • Recurrent Multiple Myeloma
          • Refractory Multiple Myeloma
          • Biospecimen Collection
          • +9 more
          • Columbus, Ohio
            Ohio State University Comprehensive Cancer Center
          Aug 1, 2023

          Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial in Beijing (6B11-OCIK Injection, Doxorubicin)

          Recruiting
          • Recurrent Ovarian Carcinoma
          • Platinum-resistant Ovarian Cancer
          • Beijing, China
            Peking University People's hospital
          Feb 11, 2022

          Melanoma Trial in Washington, Baltimore, Hackensack (Nivolumab, Ipilimumab, Cabozantinib)

          Suspended
          • Melanoma
          • Washington, District of Columbia
          • +2 more
          Jan 18, 2023

          Multiple Myeloma, Plasma Cell Tumor, Malignant Plasma Cell Tumor Trial in Houston (Radiation Therapy)

          Recruiting
          • Multiple Myeloma
          • +2 more
          • Radiation Therapy
          • Houston, Texas
            M D Anderson Cancer Center
          Jul 9, 2022